A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Tianjin Medical University Cancer Institute and Hospital
Fudan University
Ruijin Hospital
The First Affiliated Hospital of Guangzhou Medical University
Fudan University
The First Affiliated Hospital with Nanjing Medical University
First Affiliated Hospital of Guangxi Medical University
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Fudan University
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Peking Union Medical College Hospital
Shanghai Changzheng Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sun Yat-sen University
First Affiliated Hospital of Zhejiang University
Guangdong Association of Clinical Trials
Sun Yat-sen University
Sichuan University
The First Affiliated Hospital with Nanjing Medical University
Peking Union Medical College Hospital
Fudan University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
The First Affiliated Hospital with Nanjing Medical University
Jinzhou Medical University
Sun Yat-sen University
Shandong Cancer Hospital and Institute
Shandong Cancer Hospital and Institute
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Ruijin Hospital
Sun Yat-sen University
Sun Yat-sen University
Sixth Affiliated Hospital, Sun Yat-sen University
Zhejiang University
Lanzhou University Second Hospital
Fudan University
Fudan University
Tongji Hospital
Peking University
The First Affiliated Hospital of Zhengzhou University
Fudan University
Fudan University
Fudan University
Fudan University
Fudan University
Hunan Province Tumor Hospital
The First People's Hospital of Changzhou
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sun Yat-sen University
Fudan University
Zhejiang University